Kendall companies and doctors pay $810,000 to settle Medicare fraud charges
Just over $810,000 brought an end to a five-year federal court civil case in which a Kendall radiology center and some of its doctors were accused of Medicare fraud.
The settlement agreement allows Vascular and Interventional Specialists, Vascular and Spine Institute, Dr. Oscar Sosa and Dr. Osmany DeAngelo to continue to deny admitting to charging Medicare for unnecessary angioplasty procedures from Jan. 1, 2015, through Sept. 30, 2019.
But the two companies — which state corporate records say are run by Sosa, Gary Tie-Shue and Peter Clayton out of 9175 SW 87th Ave. — and the two doctors are paying $810,301 to bring this case to a conclusion.
MORE: Miami plastic surgery center once sued by 50 Cent now on suspension
Sosa has been licensed in Florida since May 2000. According to online state records, Sosa has never faced professional discipline, but state insurance records say his malpractice insurance paid $225,000 after a procedure involving two angioplasties left a patient with a 'right foot drop,' which Cleveland Clinic describes as 'a symptom in which you drag your toes when you walk due to weakness or paralysis of certain muscles in your foot.'
DeAngelo has been licensed in Florida as an osteopathic physician since May 2004. Although he has no professional discipline history, this isn't the first time he has faced trouble related to an angiogram. State insurance records say DeAngelo's malpractice insurance paid $250,000 on Aug. 31, 2021, after his 'alleged failure to fully describe findings and recommend additional treatments or transfer' after interpreting an angiogram while at Larkin Community Hospital in South Miami.
This case was originally filed by whistleblower Dr. Emilio Lopez, who provided radiology services at Vascular from Oct. 1, 2018, until Aug. 26, 2019. The False Claims Act allows Lopez to file suit on behalf of the federal government and get a cut of the money recovered. In this case, that share is $186,369.
The flow of blood — and money?
'Angioplasty is a procedure used to open blocked coronary arteries caused by coronary artery disease,' Johns Hopkins Medical Center says. 'It restores blood flow to the heart muscle without open-heart surgery.'
Angioplasty is one of the vascular and radiology services offered on an outpatient basis at Vascular, which operated out of 7887 North Kendall Dr. during the 2015-2019 period in question.
The case alleged that Vascular altered patient medical records or lied on patient medical records to make it appear as if various angioplasties were necessary. Lopez's lawsuit claimed the Vascular management tried to bring him into the alleged scheme on various levels, but he refused.
'On Aug. 23, 2019, [Lopez] again discussed the defendants' fraudulent practices with Clayton, Sosa, and DeAngelo,' the lawsuit said. 'At the meeting, Clayton, Sosa, and DeAngelo offered no explanation for how the surgeries were medically necessary and nonfraudulent. The defendants made it clear to [Lopez] that their practices would continue despite [Lopez's] repeated protestations.
'On various occasions, Sosa laughed off [Lopez's] concerns. For example, he stated that if the govenment audited VIS, DeAngelo 'would be the only one going to jail.' He also commented that 'nobody ever has to pay any of the money back.''
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
4 hours ago
- Chicago Tribune
Aurora City Council approves giving $500,000 to VNA Health Care in support of new clinic
The city of Aurora is moving forward with giving VNA Health Care $500,000 in support of its newly-opened clinic at the Bloomhaven campus on Aurora's near East Side. The Aurora City Council on Tuesday evening approved the move, despite concerns from some aldermen. The money will go toward supporting the opening of VNA's new Primary Care Center, which offers services in both English and Spanish, at 323 Weston Ave. VNA, a nonprofit, accepts patients with Medicaid, Medicare, private insurance or no insurance, with potential discounts for those without insurance. The nonprofit invested around $8 million in its new center, according to past reporting, with $500,000 pledged by city administration last July and recognized through a letter signed by former Mayor Richard Irvin and VNA CEO Linnea Windel. But the agreement never went before the City Council for approval, nor was it included in the 2025 budget. The item most likely should have gone before the City Council when the agreement was made, Aurora Chief of Staff Shannon Cameron previously said, and it appears to have been simply an oversight of the previous administration. The item was set to go to the City Council Finance Committee on May 15 but was held so more research could be done, according to past reporting. It went to the May 29 Finance Committee meeting, then came back to its meeting on June 12 with a change by Aurora Chief Financial Officer Chris Minick, who suggested the city pay the $500,000 in two installments. VNA tentatively agreed to the plan, according to past reporting. The payment is now being split in half, distributing $250,000 this year and $250,000 next year, according to past reporting. This year's payment is set to be paid using city interest earnings, and the funding source for next year's payment will be decided during the 2026 budgeting process, Minick previously said. The item was reviewed by the Committee of the Whole, and then ultimately discussed and voted on Tuesday by the City Council. Ald. Edward Bugg, 9th Ward, who had previously expressed concern about the way the agreement was approved, said on Tuesday that he had 'serious doubts' about the matter going forward. He — along with Ald. Ted Mesiacos, 3rd Ward, and Ald. Keith Larson, at-large — voted against approving the payments to VNA. But the majority of the City Council, acknowledging the potential error in the approval process, said they felt it was a worthy cause regardless. Ald. Carl Franco, 5th Ward, said it was 'unproductive' to 'keep bringing it up and throwing people under the bus' and said the council should focus on whether it's appropriate to provide the funds. 'Is it worthwhile?' Franco said. 'I don't even think it's a question.' Several council members echoed similar sentiments about the value VNA provides to the community, in spite of any possible mistakes made on the city's end. But, looking to future votes, Ald. Daniel Barreiro, 1st Ward, who noted that he was voting for the proposal 'on a non-precedent setting basis,' said the city needs to ensure a similar situation doesn't happen again. Now, with final approval secured, VNA is set to get the first installment of the payment this year for the new clinic, which opened in April, and the second half of the payment next year.
Miami Herald
6 hours ago
- Miami Herald
Kendall companies and doctors pay $810,000 to settle Medicare fraud charges
Just over $810,000 brought an end to a five-year federal court civil case in which a Kendall radiology center and some of its doctors were accused of Medicare fraud. The settlement agreement allows Vascular and Interventional Specialists, Vascular and Spine Institute, Dr. Oscar Sosa and Dr. Osmany DeAngelo to continue to deny admitting to charging Medicare for unnecessary angioplasty procedures from Jan. 1, 2015, through Sept. 30, 2019. But the two companies — which state corporate records say are run by Sosa, Gary Tie-Shue and Peter Clayton out of 9175 SW 87th Ave. — and the two doctors are paying $810,301 to bring this case to a conclusion. MORE: Miami plastic surgery center once sued by 50 Cent now on suspension Sosa has been licensed in Florida since May 2000. According to online state records, Sosa has never faced professional discipline, but state insurance records say his malpractice insurance paid $225,000 after a procedure involving two angioplasties left a patient with a 'right foot drop,' which Cleveland Clinic describes as 'a symptom in which you drag your toes when you walk due to weakness or paralysis of certain muscles in your foot.' DeAngelo has been licensed in Florida as an osteopathic physician since May 2004. Although he has no professional discipline history, this isn't the first time he has faced trouble related to an angiogram. State insurance records say DeAngelo's malpractice insurance paid $250,000 on Aug. 31, 2021, after his 'alleged failure to fully describe findings and recommend additional treatments or transfer' after interpreting an angiogram while at Larkin Community Hospital in South Miami. This case was originally filed by whistleblower Dr. Emilio Lopez, who provided radiology services at Vascular from Oct. 1, 2018, until Aug. 26, 2019. The False Claims Act allows Lopez to file suit on behalf of the federal government and get a cut of the money recovered. In this case, that share is $186,369. The flow of blood — and money? 'Angioplasty is a procedure used to open blocked coronary arteries caused by coronary artery disease,' Johns Hopkins Medical Center says. 'It restores blood flow to the heart muscle without open-heart surgery.' Angioplasty is one of the vascular and radiology services offered on an outpatient basis at Vascular, which operated out of 7887 North Kendall Dr. during the 2015-2019 period in question. The case alleged that Vascular altered patient medical records or lied on patient medical records to make it appear as if various angioplasties were necessary. Lopez's lawsuit claimed the Vascular management tried to bring him into the alleged scheme on various levels, but he refused. 'On Aug. 23, 2019, [Lopez] again discussed the defendants' fraudulent practices with Clayton, Sosa, and DeAngelo,' the lawsuit said. 'At the meeting, Clayton, Sosa, and DeAngelo offered no explanation for how the surgeries were medically necessary and nonfraudulent. The defendants made it clear to [Lopez] that their practices would continue despite [Lopez's] repeated protestations. 'On various occasions, Sosa laughed off [Lopez's] concerns. For example, he stated that if the govenment audited VIS, DeAngelo 'would be the only one going to jail.' He also commented that 'nobody ever has to pay any of the money back.''
Forbes
8 hours ago
- Forbes
InnovationRx: Health Insurers Vow To Improve Prior Authorization (Again)
In this week's edition of InnovationRx, we look at efforts to improve prior authorization, commercializing Bell Labs' IP portfolio, a new billionaire from Caris Life Sciences' IPO, a big funding round for robots to do cataract surgery, and more. To get it in your inbox, subscribe here . AFP via Getty Images On Monday, representatives from multiple health insurance companies said they had pledged to the Department of Health and Human Services that they would improve their prior authorization procedures, the bureaucratic process required for them to pay for certain tests, medications or procedures. The insurers vowed to reduce the number of claims subject to prior authorization, standardize electronic requests for them and offer 90% of approvals in real time by 2027. This isn't the first time the industry has pledged to streamline the prior authorization process. Insurers made a similar pledge during the first Trump Administration in 2018, with some of those promises echoing language in the current announcement. When Centers for Medicare & Medicaid Services Administrator Mehmet Oz was asked at a press event why he thought this effort could work when others have failed, he replied that 'there is violence in the streets over these issues now,' presumably alluding to the murder of UnitedHealthcare CEO Brian Thompson last December. The technology is better now, too, he said, and the Administration plans to back the efforts with regulation. 'Either you fix it, or we'll fix it,' Oz told the insurance company execs. Bell Labs Is Commercializing Its Historic IP Portfolio, Starting With Healthcare Nishant Batra, Nokia's chief strategy and technology officer, has made commercializing Bell Labs' IP a priority. Nokia For decades, Bell Labs' research was legendary–an innovation factory that spawned transistors, lasers and solar cells. But its researchers were always better at ideas than commercialization. Even today, lots of patents and research ideas remain tucked away in its suburban New Jersey offices. Since joining Nokia in 2021, chief strategy and technology officer Nishant Batra has been working to change that. He told Forbes that when he kicked off the commercialization effort, he thought he could spin out two or three companies a year, but now thinks he may be able to do three to five. 'The world wouldn't exist without Bell Labs, but what Bell Labs does not do well is monetization,' Batra told Forbes. A big part of the effort to change that comes with a partnership with deep tech investor Celesta, which has $1.1 billion in assets under management and with whom Nokia has co-invested in the past. The two are scouring Bell Labs' IP portfolio for pieces of technology that might have commercial applications – and the first spinout is in healthcare. That first company, called Astranu, spun out in May with a small amount of seed funding, to apply Bell Labs' imaging technology known as integrated optical coherence tomography to diagnostics of middle ear conditions. It ultimately hopes to transform ear diagnostic care with advanced, non-invasive, high-resolution 3D imaging by reducing the need for exploratory surgery and expensive MRIs 'We built this technology for optical use, for communications,' Batra said. But as Bell Labs' researchers and Celesta's investors analyzed the technology, they realized what was built for communications could be applied to creating an accurate, handheld test for the middle ear. 'Our researchers on optical said, 'this is a good application,' and our friends at Celesta said, 'we can take this to market with you,'' Batra said. Most of this hidden-away IP won't be healthcare-related, but it's intriguing that the first company to launch from the Bell Labs' portfolio is, which not only shows the breadth of its research applications, but also how many technology innovations can be adapted to help patients. 'We call it 'bioconvergence,'' said Celesta's founding managing partner Sriram Viswanathan, noting how miniaturization of technology could be extremely helpful for medical applications. 'It's the intersection of advanced AI and semiconductor-related technologies as it applies to life sciences and biotech. Think about it as diagnostics more than therapeutics….There are so many applications in the healthcare area that we see this as a natural.' BIOTECH AND PHARMA Drugmaker Novo Nordisk said on Monday that it was ending its arrangement to sell its weight-loss drug, Wegovy, through telehealth provider Hims & Hers. The pharmaceutical company accused Hims & Hers of using 'deceptive marketing' to sell knockoff versions of its drug in a statement. The stock price of Hims & Hers collapsed shortly after the announcement, cutting its market capitalization by nearly one-third to a recent $9.6 billion, pummeling the fortune of cofounder and CEO Andrew Dudum , who is no longer a billionaire. Plus : A study published in the Journal of Immunology identified a biomarker that helps predict whether colorectal patients will respond to treatment using cytokine-induced killer cells. DIGITAL HEALTH AND AI Last week, precision medicine company Caris Life Sciences went public, minting a new billionaire in founder David Dean Halbert. At the company's recent market cap of $7.4 billion, Halbert is worth at least $3.3 billion by Forbes calculations. He owns nearly 44% of the company. 'I fundamentally believed that if there was something wrong with the human body, there was something misfiring at the molecular level and technology advances could find that and diagnose it and possibly treat it,' Halbert told Forbes. Read more here. Plus : Medical scribing startup Abridge reached a valuation of $5.3 billion after raising $300 million in venture funding led by Andreessen Horowitz. The Pittsburgh-based company has surged as doctors and health systems have adopted ambient listening apps, and the new valuation is nearly double the $2.75 billion it was worth when it last raised funds in February. Cofounder and CEO Shiv Rao told Forbes that he 'wasn't surprised per se' by the new valuation because of how quickly AI is changing the way companies operate. Abridge is expanding from using ambient listening to improve the doctor-patient relationship to using the technology to help health systems with their billing and coding. 'Why we have raised capital and invested so heavily in R&D is that we are taking our models to revenue school and risk-adjustment school,' he said. MEDTECH Cataract surgery is one of the world's most common medical procedures, with more than 4 million of them done each year in the United States alone, but there simply aren't enough doctors available to meet the demand for everyone who needs the surgery. Enter robotics. An Israeli startup is betting that robots can ultimately do it better and cheaper than human doctors. ForSight Robotics on Tuesday said it had raised $125 million led by Eclipse Ventures to expand its robotic platform, called Oryom, which it says is the world's first for cataracts and other eye diseases. The funding represents one of the largest investments in a surgical robotics startup, and brings ForSight's total investment to $195 million. 'At first people were intimidated by robotics' advancement,' Dr. Joseph Nathan, ForSight's cofounder, president and chief medical officer, told Forbes. 'Now they are seeing robotics as the things that will get them the best outcomes.' Read more here. PUBLIC HEALTH AND HOSPITALS The CDC's Advisory Committee on Immunization Practices (ACIP), which makes recommendations for vaccine practices, is scheduled to meet today and tomorrow to discuss vaccines for COVID-19, flu and RSV. Senator Bill Cassidy, R-La., a physician who chairs the Health, Education, Labor and Pensions Committee, called for the panel to be delayed, citing the lack of expertise among the new appointees of HHS Secretary Robert F. Kennedy Jr. and the fact that it includes fewer members than is typical. RFK Jr. purged the vaccine advisory committee earlier this of the committee's new members have expressed skepticism about vaccines, in keeping with his own views. But a new poll from the Harvard Opinion Research Program found these attitudes to be out-of-step with the vast majority of Americans. The survey found that 79% of Americans believe that parents should be required to vaccinate their children in order to attend school, and that even among Republicans 66% held this view. Among the remainder who didn't support mandatory vaccinations, 60% believed vaccines to be safe and effective–they just prefer to leave the choice up to parents. Plus : The American Cancer Society released the latest version of its Cancer Atlas today, which found that "an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors" and urged public health officials to accordingly focus on prevention. WHAT WE'RE READING People with severe diabetes were cured in a small trial of a new stem cell-based infusion from Vertex Pharmaceuticals. The GOP is pushing Medicaid work requirements even though similar efforts in Georgia and Arkansas have fallen flat. Changes at federal health agencies leave experts concerned that the U.S. is in worse shape to handle a new pandemic than it was before 2020. Researchers say that their studies were misrepresented by Health and Human Services to unjustifiably support anti-vaccine conclusions in a memo to Congress. Arine, which has developed an AI-powered platform for medication management, raised $30 million in venture funding led by Town Hall Ventures. A new flu drug could be better than a vaccine. In a small phase 2 study, a drug developed by Cidara Therapeutics offered 76.1% protection against catching the flu versus a placebo, higher protection than many flu vaccines. MORE FROM FORBES Forbes The 36 Colleges Most At Risk From Pell Grant Cuts By Fiona Riley Forbes US And Israel Should Prepare For Destructive Iranian Cyberattacks, Ex-Intel Officer Says By Thomas Brewster Forbes How New Balance Went From 'Dad Shoe' To Scoring The No. 1 NBA Draft Prospect By Justin Birnbaum
